Physician profile
Amanda Opaskar
NPI 1134515232
$3,815.61
in general payments reported to CMS, 2019-2025
28 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what a typical Vascular Neurology provider received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $29.13 · 2021: $765 · 2022: $589 · 2023: $681 · 2024: $688 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,431.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $872.62 | 2021-2025 | |
| Ucb, INC. | $435.94 | 2021-2025 | Briviact, Nayzilam, Zilbrysq |
| Lundbeck LLC | $405.30 | 2021-2025 | Vyepti |
| Lilly USA, LLC | $342.12 | 2022-2025 | Amyvid, Kisunla, Reyvow |
| Sk Life Science, INC. | $277.03 | 2021-2025 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $235.41 | 2021-2025 | Austedo Xr, Ajovy |
| Neurocrine Biosciences, INC. | $182.59 | 2024-2025 | Ingrezza |
| Neurelis, INC. | $149.68 | 2021-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $143.42 | 2021-2023 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $124.86 | 2021-2024 | Wainua, Andexxa |
| Pfizer INC. | $116.81 | 2024-2025 | |
| Averitas Pharma INC. | $55.12 | 2024-2025 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $53.10 | 2023 | Nuedexta |
| Csl Behring | $41.39 | 2020-2025 | Kcentra, Privigen |
| Impel Pharmaceuticals LLC | $39.78 | 2024-2025 | Trudhesa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $38.40 | 2024 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Orthofix Medical, INC. | $36.41 | 2023 | Spinal-Stim, Spinal-Stim, Cervical-Stim |
| Celgene Corporation | $36.28 | 2024-2025 | Zeposia |
| Avanir Pharmaceuticals, INC. | $32.88 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $28.68 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $24.75 | 2023 | Lumryz |
| Amgen INC. | $24.25 | 2021 | |
| Medtronic, INC. | $21.62 | 2021 | |
| Eisai INC. | $21.27 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.20 | 2023 | |
| Novartis Pharmaceuticals Corporation | $19.96 | 2023 | |
| Acadia Pharmaceuticals INC | $19.45 | 2025 | Nuplazid |
| Biogen, INC. | $15.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Opaskar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.